Subtype
High-Grade Glioma, NOS
CI-CAN-00009391Explore in graph →
75 active trials2 approved drugs11 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00009391Explore in graph →
Clinical trials
173 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (30)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07416188 | Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma | recruiting | Phase 1 / Phase 2 | 40 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03340506 | Dabrafenib and/or Trametinib Rollover Study | recruiting | Phase 4 | 100 | Novartis PharmaceuticalsINDUSTRY | 14 | Sep 23, 2026 | clinicaltrials |
| NCT07031765 | Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma(Peds CHAMP1ON) | active not recruiting | Phase 1 | 12 | University of FloridaOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06357377 | A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors | recruiting | Phase 1 | 12 | Neonc Technologies, Inc.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07389278 | Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) | not yet recruiting | Phase 1 / Phase 2 | 97 | Sabine Mueller, MD, PhDOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07784985 | A Study of NST-628 in Recurrent Grade 4 Glioma | not yet recruiting | Early Phase 1 | 12 | Nader SanaiOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05698524 | A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma | recruiting | Phase 1 | 24 | University of NebraskaOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06946680 | IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Newly Diagnosed and Recurrent Pediatric High-grade Glioma (pHGG) and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (ndDIPG)(Peds IMPACT) | not yet recruiting | Phase 1 | 24 | University of FloridaOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07644312 | Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG | not yet recruiting | Phase 2 | 12 | Nationwide Children's HospitalOTHER | 0 | Sep 9, 2026 | clinicaltrials |
| NCT05839379 | Targeted Pediatric High-Grade Glioma Therapy | recruiting | — | 350 | Nationwide Children's HospitalOTHER | 7 | Sep 8, 2026 | clinicaltrials |
| NCT05538130 | A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors | active not recruiting | Phase 1 | 148 | PfizerINDUSTRY | 7 | Sep 1, 2026 | clinicaltrials |
| NCT06161974 | Study of Olutasidenib and Temozolomide in HGG | recruiting | Phase 2 | 60 | Rigel PharmaceuticalsINDUSTRY | 7 | Sep 1, 2026 | clinicaltrials |
| NCT07788677 | Tarlatamab Treatment Before and After Surgery in Surgically Resectable Recurrent High-grade Glioma: a Window of Opportunity Study (TARLAGLIA Study)(TARLAGLIA) | not yet recruiting | Phase 1 | 10 | Vall d'Hebron Institute of OncologyOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05096481 | PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma | recruiting | Phase 2 | 120 | Nationwide Children's HospitalOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05632562 | Multiparametic Metabolic and Hypoxic PET/MRI for Disease Assessment in High Grade Glioma | recruiting | Early Phase 1 | 20 | University of Alabama at BirminghamOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04485559 | Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021) | recruiting | Phase 1 | 50 | University of California, San FranciscoOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT05212272 | MRI in High-Grade Glioma Patients Undergoing Chemoradiation | recruiting | N/A | 16 | Wake Forest University Health SciencesOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07751744 | Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma | not yet recruiting | Phase 1 / Phase 2 | 113 | Jubilant Therapeutics Inc.INDUSTRY | 0 | Aug 7, 2026 | clinicaltrials |
| NCT05565118 | Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression | recruiting | Phase 1 | 10 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT04099797 | C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) | recruiting | Phase 1 | 56 | Baylor College of MedicineOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06624371 | Atovaquone Combined With Radiation in Children With Malignant Brain Tumors(AflacBT2303) | recruiting | Phase 1 | 18 | Emory UniversityOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07206849 | Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG) | not yet recruiting | Phase 2 | 79 | Nationwide Children's HospitalOTHER | 0 | Jul 31, 2026 | clinicaltrials |
| NCT05023551 | Study of DSP-0390 in Patients With Recurrent High-Grade Glioma | active not recruiting | Early Phase 1 | 39 | Sumitomo Pharma America, Inc.INDUSTRY | 2 | Jul 29, 2026 | clinicaltrials |
| NCT07725640 | Feasibility Assessment of a Medical Device for Tumour Cell Retention and Radiotherapy Sensitization in Patients With Suspected High-grade Glioma(CT-GlioHook) | not yet recruiting | N/A | 15 | Batea OncologyINDUSTRY | 1 | Jul 27, 2026 | clinicaltrials |
| NCT05278208 | Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors | recruiting | Phase 1 / Phase 2 | 65 | Nationwide Children's HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07710690 | A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade Glioma | recruiting | Phase 1 | 24 | Neuregen Therapeutics Co., Ltd.INDUSTRY | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07472790 | A Study on the Novel Oncolytic Virus Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade Glioma | not yet recruiting | Phase 1 | 15 | Beijing Bio-Targeting Therapeutics Technology Co., LtdINDUSTRY | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06888817 | Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases(BRAINS) | recruiting | Phase 3 | 408 | The Netherlands Cancer InstituteOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06712875 | MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas | recruiting | Phase 1 / Phase 2 | 27 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05835687 | Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors | active not recruiting | Phase 1 | 29 | St. Jude Children's Research HospitalOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07210632 | Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG) | recruiting | Early Phase 1 | 38 | Eben RosenthalOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06333899 | Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion | recruiting | Early Phase 1 | 15 | Nationwide Children's HospitalOTHER | 6 | Jun 29, 2026 | clinicaltrials |
| NCT04573140 | A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)(PNOC020) | recruiting | Phase 1 | 28 | University of FloridaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06428045 | STARLITE for Unresectable High-Grade Gliomas(STARLITE) | recruiting | Phase 1 | 24 | University of MiamiOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT05954858 | Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma | recruiting | N/A | 32 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05979064 | Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM) | recruiting | N/A | 10 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05843253 | Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant | recruiting | Phase 2 | 120 | Nationwide Children's HospitalOTHER | 6 | May 29, 2026 | clinicaltrials |
| NCT07609472 | FG001 Near-Infrared Fluorescence Imaging During Tumor Resection in Newly Diagnosed High-Grade Glioma | not yet recruiting | Phase 2 | 76 | FluoGuide A/SINDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT06264388 | DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma | recruiting | Phase 2 | 33 | Ashish ShahOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07424092 | Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors(PED-DNX2401) | recruiting | Phase 2 | 39 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 2 | May 27, 2026 | clinicaltrials |
| NCT06724926 | Concurrent Azeliragon With Craniospinal Irradiation | active not recruiting | Phase 1 | 21 | NYU Langone HealthOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT06528691 | Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors | recruiting | Phase 2 | 52 | St. Jude Children's Research HospitalOTHER | 4 | May 13, 2026 | clinicaltrials |
| NCT07567196 | PET-Guided Resection in High-Grade Gliomas(ResPGlioma) | recruiting | — | 100 | Universita degli Studi di GenovaOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07567469 | A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma | not yet recruiting | Phase 1 / Phase 2 | 120 | Regeneron PharmaceuticalsINDUSTRY | 0 | May 5, 2026 | clinicaltrials |
| NCT06126744 | Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252(PuMP) | recruiting | Phase 1 | 51 | Duke UniversityOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07532031 | APT-weighted and Diffusion MRI for Characterizing Tumor Infiltration in High-Grade Gliomas(APT-HGG) | not yet recruiting | — | 20 | IRCCS Ospedale San RaffaeleOTHER | 0 | Apr 15, 2026 | clinicaltrials |
| NCT07488754 | Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) In Newly Diagnosed Glioma (WHO G3-G4) | recruiting | N/A | 35 | Medical University of WarsawOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT03605550 | A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma | active not recruiting | Phase 1 | 64 | Nationwide Children's HospitalOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06482905 | Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma. | recruiting | Phase 1 | 52 | Tcelltech Inc.INDUSTRY | 2 | Mar 24, 2026 | clinicaltrials |
| NCT06763965 | Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma. | enrolling by invitation | Phase 1 / Phase 2 | 30 | Beijing Bio-Targeting Therapeutics Technology Co., LtdINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
Data updated 2 days agoSource updated Sep 28, 2026source: clinicaltrials